Ensysce Biosciences Inc (ENSC) USD0.0001
$0.15
(1.89%)
- Add to watchlist
- This stock can be held in a
$0.15
(1.89%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.15
(1.89%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Contact details
Important dates
General stock information
- Short code:
- ENSC
- ISIN:
- US2936025046
- Market cap:
- $6.04 million
- Shares in issue:
- 994,275
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.